On 28 January 2015, in two separate decisions, the European Commission conditionally approved a complex transaction between pharmaceuticals producers GlaxoSmithKline (GSK) and Novartis that will result in: (i) GSK’s acquisition of Novartis’ human vaccines business; (ii) the formation of a joint venture for consumer healthcare; and (iii) the acquisition by Novartis of GSK’s oncology business. Each element of the transaction involved significant commitments by the parties to address competition concerns.
Share on
|
|
The EU Commission conditionally approves a three-part deal in the pharmaceutical sector (Novartis / GSK)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
